Corvus Pharmaceuticals Inc (CRVS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

863 MITTEN ROAD BURLINGAME, CA 94010

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.

Data as of 2021-09-11 11:36:17 -0400
Market Cap105.204 Million Shares Outstanding42.421 Million Avg 30-day Volume252.369 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.98355 52-week High/Low5.74 / 1.86 Next Earnings Date2021-10-28 Price to Cash FLow (P/CF) -8.7053
Data provided by IEX Cloud
View SEC Filings from CRVS instead.

View recent insider trading info

Funds Holding CRVS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRVS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

10 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LEA LEIV CHIEF FINANCIAL OFFICER

  • Officer
160,000 2021-09-09 2

MILLER RICHARD A MD PRESIDENT AND CEO

  • Officer
  • Director
320,000 2021-09-09 5

ADAMS STREET PARTNERS LLC

  • 10% Owner
3,290,616 2021-09-09 2

CLARK IAN T

  • Director
15,000 2021-09-09 2

THOMPSON PETER A.

  • Director
  • 10% Owner
8,068,298 2021-09-09 3

GRAIS LINDA

  • Director
15,000 2021-09-09 2

MITCHELL EDITH P.

  • Director
15,000 2021-09-09 2

GOULD TERRY P

  • Director
  • 10% Owner
3,290,616 2021-09-09 2

MORRISON SCOTT W

  • Director
15,000 2021-09-09 2

JONES WILLIAM BENTON SEE REMARKS

  • Officer
160,000 2021-09-09 2

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

  • Director
  • 10% Owner
8,053,298 2021-02-17 1

MOBASHER MEHRDAD SVP, CHIEF MEDICAL OFFICER

  • Officer
0 2020-12-16 1

NOVO HOLDINGS A/S

  • 10% Owner
No longer subject to file 2020-07-07 0

KROGNES STEVE E.

  • Director
0 2020-06-09 0

BUGGY JOSEPH J EVP, DISCOVERY RESEARCH

  • Officer
0 2019-12-12 0

VERNER ERIK J. VP, CHEMISTRY RESEARCH

  • Officer
0 2019-12-12 0

HUNT DANIEL W. SVP, CHIEF BUSINESS OFFICER

  • Officer
0 2019-12-12 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • Director
  • 10% Owner
5,379,349 2016-06-23 0

COLOMA JASON V SVP, CHIEF BUSINESS OFFICER

  • Officer
0 2016-06-08 0

ORBIMED ADVISORS LLC

  • Director
  • 10% Owner
5,258,450 2016-03-29 0

MOLDT PETER

  • Director
0 2016-03-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

GRAIS LINDA - Director

2021-09-13 16:56:13 -0400 2021-09-09 A 15,000 a 15,000 direct

GOULD TERRY P - Director - > 10% Owner

2021-09-13 16:53:53 -0400 2021-09-09 A 15,000 a 15,000 direct

CLARK IAN T - Director

2021-09-13 16:48:53 -0400 2021-09-09 A 15,000 a 15,000 direct

LEA LEIV - Officer CHIEF FINANCIAL OFFICER

2021-09-13 16:59:52 -0400 2021-09-09 A 160,000 a 160,000 direct

JONES WILLIAM BENTON - Officer SEE REMARKS

2021-09-13 16:57:56 -0400 2021-09-09 A 160,000 a 160,000 direct

MITCHELL EDITH P. - Director

2021-09-13 16:55:15 -0400 2021-09-09 A 15,000 a 15,000 direct

ADAMS STREET PARTNERS LLC - > 10% Owner see footnote

2021-09-13 16:02:42 -0400 2021-09-09 A 15,000 a 15,000 indirect

MILLER RICHARD A MD - Director - Officer PRESIDENT AND CEO

2021-09-13 17:00:55 -0400 2021-09-09 A 320,000 a 320,000 direct

THOMPSON PETER A. - Director - > 10% Owner

2021-09-13 16:53:12 -0400 2021-09-09 A 15,000 a 15,000 direct

MORRISON SCOTT W - Director

2021-09-13 16:51:22 -0400 2021-09-09 A 15,000 a 15,000 direct

MILLER RICHARD A MD - Director - Officer PRESIDENT AND CEO by trust

2021-08-23 21:01:46 -0400 2021-08-20 P 10,000 $1.93 a 1,288,515 indirect 6.7308 8.6538 8.6538 6 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CORVUS PHARMACEUTICALS INC CRVS 2021-09-20 22:15:03 UTC -8.2784 8.3484 600
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 22:15:03 UTC -3.5404 3.6104 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 21:45:03 UTC -3.5404 3.6104 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 21:15:03 UTC -3.5404 3.6104 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 20:45:02 UTC -3.4956 3.5656 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 20:15:03 UTC -3.4956 3.5656 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 19:45:03 UTC -3.4956 3.5656 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 19:15:02 UTC -3.4956 3.5656 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 18:45:03 UTC -3.1485 3.2185 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 18:15:03 UTC -3.1485 3.2185 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 17:45:03 UTC -3.1485 3.2185 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 17:15:03 UTC -3.1485 3.2185 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 16:45:03 UTC -3.1485 3.2185 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 16:15:04 UTC -3.1485 3.2185 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 15:45:03 UTC -3.1485 3.2185 300000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 15:15:03 UTC -3.1485 3.2185 250000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 14:45:03 UTC -3.4641 3.5341 250000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 14:15:03 UTC -3.4641 3.5341 250000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 13:45:03 UTC -3.4641 3.5341 250000
CORVUS PHARMACEUTICALS INC CRVS 2021-09-16 13:15:03 UTC -3.4641 3.5341 250000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments